FFCP PHASE2:Hg19::chr2:42329629..42329640,+
From FANTOM5_SSTAR
Jump to: navigation, search
| Short description: | p@chr2:42329629..42329640, + |
|---|---|
| Species: | Human (Homo sapiens) |
| DPI dataset: | Robust |
| TSS-like-by-RIKEN-classifier(Yes/No): | Yes |
| DHS support(Yes/No): | Yes |
| Description: | CAGE_peak_at_chr2:42329629..42329640, + |
| Coexpression cluster: | C6_CD14_Eosinophils_Basophils_Peripheral_CD34_Natural_immature |
| Association with transcript: | NA |
| EntrezGene: | NA |
| HGNC: | NA |
| UniProt: | NA |
| Genome view: | ZENBU |
View on UCSC genome browser
Mouse over to see Genome browser image, Click image to go to Genome browser
CAGE Expression
| Sample | p@chr2:42329629..42329640+ |
|---|
0
1
2
3
4
5
6
7
- Click each plot point to find sample in table
Ontology-based sample term enrichment analysis<b>Summary:</b>This analysis has been performed by utilizing wilcoxon rank sum test.When the number of associated cells/tissues are > n , randomly sampled n cells/tissues are used for P value calculation with rank sum test. this process are repeated several times, and the P values are averaged on the log space <br><b>Analyst:</b> Hideya Kawaji<br><br>link to source dataset<br>data
| Ontology term | p-value | n |
|---|---|---|
| classical monocyte | 2.86e-21 | 42 |
| CD14-positive, CD16-negative classical monocyte | 2.86e-21 | 42 |
| eosinophil | 3.02e-20 | 2 |
| myeloid leukocyte | 4.61e-20 | 72 |
| defensive cell | 1.96e-18 | 48 |
| phagocyte | 1.96e-18 | 48 |
| leukocyte | 1.64e-17 | 136 |
| CD4-positive, alpha-beta T cell | 5.06e-15 | 6 |
| monopoietic cell | 1.85e-14 | 59 |
| monocyte | 1.85e-14 | 59 |
Showing 1 to 10 of 37 entries
| Ontology term | p-value | n |
|---|---|---|
| hematopoietic system | 5.86e-12 | 98 |
| blood island | 5.86e-12 | 98 |
| bone marrow | 6.06e-11 | 76 |
| hemolymphoid system | 1.10e-10 | 108 |
| immune system | 1.31e-10 | 93 |
| bone element | 4.79e-10 | 82 |
| skeletal element | 4.94e-09 | 90 |
| skeletal system | 5.43e-08 | 100 |
Showing 1 to 8 of 8 entries
